Retatrutide: FDA records on compounded and unapproved products
Has FDA taken action on compounded retatrutide?
Yes. As of Nov 15, 2026, FDA has issued 21 warning letters to 21 companies whose text names retatrutide, the latest dated Aug 24, 2026, and openFDA lists 1 recall report naming it. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs (FDA page current as of Oct 1, 2026).
As of Nov 15, 2026, FDA’s drug shortage data lists no retatrutide products.
What FDA has stated, by date
- Oct 1, 2026: FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs. FDA states it has warned telehealth companies for marketing unapproved drugs such as retatrutide, API distributors for selling retatrutide and other GLP-1 drugs to compounders, and outsourcing facilities for repackaging retatrutide. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption,” sold directly to consumers with dosing instructions. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.
FDA drug shortage status
No retatrutide entries in FDA’s drug shortage data as of Nov 15, 2026.
Active ingredient (API) imports: FDA import alert and refusal records
FDA’s Import Alert 66-80 Green List (published Oct 9, 2026) has no entry naming retatrutide. FDA’s import refusal records list 11 refused shipment lines whose product code names retatrutide, from Jul 24, 2026 to Oct 13, 2026, most often from Canada (3), Vietnam (3) and China (2); 0 carry an API or powder product code listed on the alert.
Refused retatrutide lines by country and form
| Canada | 3 |
| Vietnam | 3 |
| China | 2 |
| Lithuania | 1 |
| Poland | 1 |
| Switzerland | 1 |
| Code not listed on Import Alert 66-80 | 11 |
Most recent refused retatrutide lines
| Shipment ID | |||||
|---|---|---|---|---|---|
| Oct 13, 2026 | UAB LABOCHEMA LT | Lithuania | 61PIP78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-0240047-2/10002/1A |
| Oct 7, 2026 | SHANGHAI SHUNYI TRADE CO LTD | China | 61PIR78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | XXX-0763321-9/1/2 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | XXX-0763336-3/1/1 |
| Oct 2, 2026 | MetaTide Healthcare | Switzerland | 61PCK78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | XXX-0759691-4/1/1 |
| Sep 24, 2026 | COMEM NATURAL JSC | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-2060079-8/20002/1D |
| Sep 24, 2026 | COMEM NATURAL JSC | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-2060079-8/20002/1H |
| Sep 24, 2026 | COMEM NATURAL JSC | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-2060079-8/20002/1I |
| Aug 25, 2026 | N EDGE GROUP INC | Canada | 61PCY78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-1683942-6/10002/1 |
| Aug 25, 2026 | N EDGE GROUP INC | Canada | 61PCY78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-1683962-4/10002/1 |
| Aug 25, 2026 | N EDGE GROUP INC | Canada | 61PCY78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-1684201-6/10002/1 |
| Jul 24, 2026 | Name not shown | Poland | 61PCY78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-3061901-9/10002/1 |
All firms and countries: Firms on GLP-1 import records.
FDA NDC Directory listings
FDA’s NDC Directory files read Nov 15, 2026 carry 11 listings naming retatrutide: BULK INGREDIENT (10); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (1). Every listing: GLP-1 listings in FDA’s NDC Directory. FDA says an NDC “does not in any way denote FDA approval of the product.”
Medicare and Medicaid spending on retatrutide
CMS’s Medicare Part D Spending by Drug file (2020 to 2024) and Medicaid State Drug Utilization Data (2020 to 2026), read Nov 15, 2026, were searched for retatrutide by generic and product name; neither lists a product under that name. Other GLP-1 drugs: Medicare and Medicaid spending on GLP-1 drugs.
FDA warning letters naming retatrutide
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Aug 24, 2026 | TXP Innovations LLC dba Tex Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Royal Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | NuScience Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peptide Partners LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peak Performance Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Prime Sciences | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Mile High Compounds LLC | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Lovega LLC dba Pink Pony Peptides | Unapproved New Drugs Sold Over the Internet | Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Gram Peptides | Unapproved New Drugs Sold Over the Internet | Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jan 20, 2026 | GenoGenix LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 8, 2025 | Darmerica, LLC | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated/Misbranded | Retatrutide, Cagrilintide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Amazing Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GenLabMeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | MedClub by Dr. Jenn | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GLP-1 Solution | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | ASN-LABS | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | EA WORKS Limited Liability Company dba Trust Labs | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Prime Vitality, Inc. dba Prime Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Swisschems | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Xcel Research LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Cagrilintide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Summit Research Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Recalls naming retatrutide
| Record | ||||||
|---|---|---|---|---|---|---|
| Jul 30, 2025 | GenoGenix LLC | Retatrutide for Injection, 60mg / 10mL vial, all presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692 | Lack of Assurance of Sterility | Class II | Ongoing | D-0093-2026 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- openFDA drug recall enforcement reports
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- CMS Medicare Part D Spending by Drug (data.cms.gov)
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.